TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy participants ≥6 months and ≤45 years of age at enrolment~2. Participants/Parents/Legally Authorized Representative(LAR) willing to give written informed consent/assent to participate in the trial~3. Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study~4. Participants who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests~5. Female participants must have a negative serum (at Screening) and negative urinary (at Day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90 days after vaccination.~Exclusion Criteria:~1. Participants/Parents/LAR unwilling to give his/her consent/assent to participate in the trial~2. Participants concomitantly enrolled or scheduled to be enrolled in another trial~3. Children and infants with a congenital abnormality~4. Known history of immune function disorders including immunodeficiency disease, or chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs~5. Pregnant, lactating women or women of childbearing age not using a reliable method of contraception~6. History of uncontrolled coagulopathy or blood disorders~7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives~8. History of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Vi-CRM197, Batch #1) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
- Arm A (Vi-CRM197, Batch #2) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
- Arm A (Vi-CRM197, Batch #3) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
- Arm D (Typbar-TCV) (Type: ACTIVE_COMPARATOR): Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult chemotherapy naïve patients of at least 18 years old~2. Diagnosed with a malignant disease and scheduled for highly emetogenic chemotherapy (as defined by NCCN guidelines v1.2019)~3. No concurrent radiotherapy or use of other antiemetic drugs except (dexamethasone, ondansetron/granisetron, and olanzapine)~4. Normal renal and hepatic function~Exclusion Criteria:~1. Pregnant or breast feeding~2. Contraindication for capsaicin or other medications in the study~3. Has ongoing nausea and/or vomiting of other etiology~4. History of anticipatory nausea and/or vomiting or has vomited/nauseated within 24 hours prior to the start of scheduled chemotherapy~5. Chronic alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capsaicin (Type: EXPERIMENTAL): 2g of 0.075% topical capsaicin ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
- Placebo (Type: PLACEBO_COMPARATOR): 2g of topical placebo ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and may be currently treated with a stable regimen of antihyperglycemic agent(s)~* Patients in the study must have a HbA1c between \>=7 and \<=10.0%~* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Ketamine-Induced Agitation, by Midazolam or Haloperidol Premedication After Adult Procedural Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient older than 18, who need to sedate in Emergency Department~Exclusion Criteria:~* age younger than 18 years,~* patients with significant cardiovascular disease,congestive heart failure (CHF)~* central nervous system lesions or injuries, increased intracranial pressure (ICP)~* ocular pathology, increased intraocular pressure (IOP)~* thyroid disease,~* acute pulmonary infections,~* conditions requiring stimulation of the posterior pharynx,~* had ingested solid food in the previous 4 hours or clear liquids in the previous 2 hours.~* Acute intermittent porphyria~* Alcoholism~* Hepatic Impairment~* Myasthenia gravis~* Respiratory depression~* allergy to haloperidol as established by direct questioning of family members and available medical history,~* moderate to severe dementia as documented by medical history,~* Parkinson's disease,~* corrected QTc interval (QTc) greater than 500 ms,~* usage of drugs prolonging QT-interval,~* history of torsades de pointes,~* history of neuroleptic malignant syndrome,~* family history of dystonic reactions to drugs,~* epilepsy or history of seizures~* chronic psychiatric disease,~* intoxication~* bone marrow suppression~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
- midazolam (Type: EXPERIMENTAL): To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
- haloperidol (Type: EXPERIMENTAL): To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma~* No previous treatment~* Clinical stage II, III, or IV by the Ann Arbor Staging Criteria~* Age \> 70 years~* ECOG performance status 0, 1, or 2~* Adequate bone marrow, liver and kidney function~* Must give written informed consent prior to entering this trial~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Central nervous system involvement with lymphoma~* Coexistent active malignancies treated within five years~* Active infection precluding the use of combination chemotherapy~* HIV infection~* Pregnant or lactating~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone (Type: EXPERIMENTAL): All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and older~* history of opioid dependence~* significant current opioid use~Exclusion Criteria:~* unstable medical or psychiatric conditions~* pregnancy~* incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Computer delivered CRA + CM + Suboxone (Type: ACTIVE_COMPARATOR): In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples.
- CM + Suboxone (Type: ACTIVE_COMPARATOR): In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer delivered therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult and teenage (\>/=16) male or female who will undergo surgery for multilevel (\>4 level) spinal fusion from a posterior approach with general anesthesia, and who are fluent English speakers such that they can complete the pain score and satisfaction questionnaires whose scores are a critical outcome variable.~* If female, subject is non-lactating and is either:~* Not of childbearing potential~* Of childbearing potential but is not pregnant at time of baseline as determined by pre-surgical pregnancy testing.~* Subject is ASA physical status 1, 2, or 3.~Exclusion Criteria:~* anxiety~* psychiatric disorder~* Allergy or sensitivity to ketamine or dilaudid~* Deemed un-acceptable by study team~* Cognitively impaired (by history)~* Subject requires chronic antipsychotic medication~* Subject known to be in liver failure~* Subject for whom opioids or ketamine are contraindicated~* Patients with narrow angle glaucoma~* Patients with a history of psychosis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine Naive (Type: ACTIVE_COMPARATOR): After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours.
- Naive Placebo (Type: PLACEBO_COMPARATOR): Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
- Tolerant Placebo (Type: PLACEBO_COMPARATOR): Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
- Tolerant Ketamine (Type: EXPERIMENTAL): After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with subfoveal neovascular AMD with either classic/predominantly classic or occult lesions~* visual acuity =\> 20/200~Exclusion Criteria:~* subretinal fibrosis or atrophy under the fovea~* patients previously treated for neovascular AMD in the study eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TTT (Type: ACTIVE_COMPARATOR): TTT is given every three months
- Sham TTT (Type: SHAM_COMPARATOR): Sham TTT is given every three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is currently taking a stable dose of lipid lowering agent(s). (if applicable) or is statin naive~* Participant is currently taking a stable dose of lipid lowering agent(s). (if is at least moderate high risk for Coronary Heart Disease (CHD))~* Participant is currently taking a stable dose of lipid lowering agent(s). (if is willing to maintain Therapeutic Lifestyle Changes (TLC) / American Diabetes Association(ADA) diet)~Exclusion Criteria:~* Participant weighs less than 100 lbs (45 kg).~* Participant has hypersensitivity or intolerance to ezetimibe, or rosuvastatin or any components of these medications.~* If female, participant is pregnant or breastfeeding.~* Participant consumes more than 2 alcoholic beverages per day.~* Participant has been in a clinical trial within the last 30 days.~* Participant has heart problems such as CHF, unstable angina or heart attack.~* Participant has type 1 or 2 diabetes and has changed their medication in the last 2 months.~* Participant has liver disease.~* Participant is Human Immunodeficiency Virus (HIV) positive.~* Participant has a history of drug or alcohol abuse in the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 5 mg + Ezetimibe 10 mg (Type: EXPERIMENTAL): Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
- Rosuvastatin 10 mg (Type: ACTIVE_COMPARATOR): Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
- Rosuvastatin 10 mg + Ezetimibe 10 mg (Type: EXPERIMENTAL): Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
- Rosuvastatin 20 mg (Type: ACTIVE_COMPARATOR): Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Diagnosis of alcohol dependence based on Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) criteria~* Male or non-pregnant, non-lactating female~* Able to provide TimeLine Follow-Back (TLFB) alcohol consumption information for 90-day period before detoxification and/or screening~* At least 2 episodes of heavy alcohol drinking per week during the 30 days before detoxification and/or screening~* Negative urine toxicological screen for opiates on day of randomization~* Noncustodial, stable residence and phone plus 1 contact with verifiable address and phone~Primary Exclusion Criteria:~* Evidence of hepatic failure including: ascites, prolonged prothrombin time (PT) (international normalized ratio \[INR\] ≥1.7), bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Active hepatitis and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) higher than 3xULN~* History of pancreatitis~* Major depression with suicidal ideation, psychosis, bipolar disorder, or psychiatric disorders that would compromise subject's ability to complete the study~* Current dependence (within past year) per DSM-IV criteria to benzodiazepines, opioids or cocaine~* Use of benzodiazepines and/or Ambien® (zolpidem tartrate) within 7 days prior to first dose of study medication~* Greater than 7 days inpatient treatment for substance use disorders within 30 days of randomization~* Use of any opioids and/or methadone within 14 days of screening, or likely requiring opioid therapy during study period~* Use of oral naltrexone or disulfiram within 14 days of screening~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medisorb naltrexone 190 mg (Type: EXPERIMENTAL): None
- Medisorb naltrexone 380 mg (Type: EXPERIMENTAL): None
- Placebo for Medisorb naltrexone 190 mg (Type: PLACEBO_COMPARATOR): None
- Placebo for Medisorb naltrexone 380 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory systemic ALCL who have previously received front line chemotherapy.~* Documented anaplastic lymphoma kinase (ALK) status.~* Histologically-confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.~* Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.~* Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.~* At US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.~Exclusion Criteria:~* Previous treatment with brentuximab vedotin.~* Previously received an allogeneic transplant.~* Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible).~* Known cerebral/meningeal disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete